The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to request global regulatory approval this year, the company said Tuesday.

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

GLP-1 receptor agonists such as the popular weight loss/diabetes therapies Mounjaro, developed by Eli Lilly (NYSE:LLY), and ...

GLP-1 receptor agonists may reduce cancer risk among people with obesity or overweight, according to retrospective study results.Adults who used GLP-1 medications exhibited a statistically significant ...

Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...

The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

Serena Williams sparked a heated debate after revealing she lost 31 pounds using a GLP-1 drug. While the tennis legend ...

The only safety endpoint associated with GLP-1 receptor agonist use was a 49% increased risk of diabetic retinopathy (aHR, 1.49; 1.11-2.00; P =.008).

GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research ...